Hold på aksjene
Ingenting er forandret siden 22 august:
Artikkel av: Stian Jacobsen
22. august 2019 - 13.24
Lest av
44179
BerGenBio er en aksje som har svingt mye de siste årene. Den siste tiden har aksjen stort sett vært forbundet med kursfall.
Nå velger analytiker Pål Falck i Arctic Securities å kutte kursmålet fra 70 til 65 kroner samtidig som han gjentar sin kjøpsanbefaling.
Det som er oppsiktsvekkende er at det skjer samtidig som aksjen omsettes for 12,76 kroner (-2,15 prosent).
Hittil i år har faktisk BerGenBio falt 52,21 prosent på Oslo Børs.
For at kursmålet skal innfris må aksjen stige utrolige 409,40 prosent fra dagens nivå.
Bloomberg kan fortelle at fem av fem analytikere som følger selskapet opererer med en kjøpsanbefaling. Det viser seg faktisk at kursmålet varierer fra 44 til 65 kroner.
Mandag denne uken la BerGenBio frem sine kvartalstall. Selskapet fikk et resultat på minus 52,8 millioner kroner i 2. kvartal 2019, mot minus 49,2 millioner kroner for et år siden.
Omsetningen ble kroner null, akkurat som året før.
Selskapet hadde ved utgangen av kvartalet 324,4 millioner kroner i kontanter, mot 441,3 millioner kroner året før.
Redigert 20.01.2021 kl 21:06
Du må logge inn for å svare
Hvorfor skal vi holde på aksjene når ledelsen lemper dem ut?
Redigert 20.01.2021 kl 21:06
Du må logge inn for å svare
FAR100
29.08.2019 kl 16:17
1195
Les melding:
Noen aksjer ble solgt for å finansiere større kjøp. Direktører har ikke million lønn i Bergen BIO
Bergen, Norway, 28 August 2019. The Board of Directors of BerGenBio ASA (the "Company") (OSE: BGBIO) have, to fulfil the Company's obligations under the share
option agreements and in accordance with the authorisation granted by the general meeting on 13 March 2019, resolved to increase the Company's share capital by
NOK 54,000 by issuance of 540,000 new shares. The new shares are subscribed for by option owners that wish, and are entitled, to exercise options in accordance
with the Company's option scheme. The subscription price is in accordance with the prevailing options price pursuant to the Company's option scheme, an average
NOK 8.39 per share. Options which have been exercised have been granted between 2010 and 2012 and all options will expire in 2019 if not exercised.
Out of the total number of exercised share options, 225,000 share options at an average strike price at NOK 8.15 were exercised by primary insider Richard
Godfrey (CEO). Richard Godfrey has transferred his rights to receive shares resulting from the exercise of options to a third party to cover all cost related to
the exercise and will keep the remaining shares from the exercise. The sales amount will be finally determined on the basis of the price subsequently obtained
by the third party when selling the shares in the market. Final compensation for the transferred rights and number of shares received from the transaction will
be reported when known. After exercising options, Richard Godfrey holds 1,129,284 unexercised options in the Company. As of today, Richard Godfrey holds 167,815
shares in the Company through Gnist Holding AS.
Out of the total number of exercised share options, 150,000 share options at an average strike price at NOK 8.45 were exercised by primary insider James Lorens,
CSO. James Lorens has transferred his rights to receive shares resulting from the exercise of options to a third party to cover all cost related to the exercise
and will keep the remaining shares from the exercise. The sales amount will be finally determined on the basis of the price subsequently obtained by the third
party when selling the shares in the market. Final compensation for the transferred rights and number of shares received from the transaction will be reported
when known. After exercising options, James Lorens holds 588,507 unexercised options in the Company. As of today, James Lorens holds 250,000 shares in the
Company.
Out of the total number of exercised share options, 15,000 share options at an average strike price at NOK 10.62 were exercised by primary insider Endre
Kjærland, Associate Director of IP and Contracts. Endre Kjærland has transferred his rights to receive shares resulting from the exercise of options to a third
party to cover all cost related to the exercise and will keep the remaining shares from the exercise. The sales amount will be finally determined on the basis
of the price subsequently obtained by the third party when selling the shares in the market. Final compensation for the transferred rights and number of shares
received from the transaction will be reported when known. After exercising options, Endre Kjærland holds 88,525 unexercised options in the Company. As of
today, Endre Kjærland holds 1,508 shares in the Company.
The capital increase is expected to be registered within 7 days, and following the issuance of the new shares, the issued share capital of BerGenBio ASA will be
NOK 6,107,659 consisting of 61,076,590 shares, each with a par value of NOK 0.10.
-End-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important
factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or
implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Html version:
- https://publish.ne.cision.com//Release/ViewReleaseHtml/8920B327D17E753BE0C856B0705FC7D6
Noen aksjer ble solgt for å finansiere større kjøp. Direktører har ikke million lønn i Bergen BIO
Bergen, Norway, 28 August 2019. The Board of Directors of BerGenBio ASA (the "Company") (OSE: BGBIO) have, to fulfil the Company's obligations under the share
option agreements and in accordance with the authorisation granted by the general meeting on 13 March 2019, resolved to increase the Company's share capital by
NOK 54,000 by issuance of 540,000 new shares. The new shares are subscribed for by option owners that wish, and are entitled, to exercise options in accordance
with the Company's option scheme. The subscription price is in accordance with the prevailing options price pursuant to the Company's option scheme, an average
NOK 8.39 per share. Options which have been exercised have been granted between 2010 and 2012 and all options will expire in 2019 if not exercised.
Out of the total number of exercised share options, 225,000 share options at an average strike price at NOK 8.15 were exercised by primary insider Richard
Godfrey (CEO). Richard Godfrey has transferred his rights to receive shares resulting from the exercise of options to a third party to cover all cost related to
the exercise and will keep the remaining shares from the exercise. The sales amount will be finally determined on the basis of the price subsequently obtained
by the third party when selling the shares in the market. Final compensation for the transferred rights and number of shares received from the transaction will
be reported when known. After exercising options, Richard Godfrey holds 1,129,284 unexercised options in the Company. As of today, Richard Godfrey holds 167,815
shares in the Company through Gnist Holding AS.
Out of the total number of exercised share options, 150,000 share options at an average strike price at NOK 8.45 were exercised by primary insider James Lorens,
CSO. James Lorens has transferred his rights to receive shares resulting from the exercise of options to a third party to cover all cost related to the exercise
and will keep the remaining shares from the exercise. The sales amount will be finally determined on the basis of the price subsequently obtained by the third
party when selling the shares in the market. Final compensation for the transferred rights and number of shares received from the transaction will be reported
when known. After exercising options, James Lorens holds 588,507 unexercised options in the Company. As of today, James Lorens holds 250,000 shares in the
Company.
Out of the total number of exercised share options, 15,000 share options at an average strike price at NOK 10.62 were exercised by primary insider Endre
Kjærland, Associate Director of IP and Contracts. Endre Kjærland has transferred his rights to receive shares resulting from the exercise of options to a third
party to cover all cost related to the exercise and will keep the remaining shares from the exercise. The sales amount will be finally determined on the basis
of the price subsequently obtained by the third party when selling the shares in the market. Final compensation for the transferred rights and number of shares
received from the transaction will be reported when known. After exercising options, Endre Kjærland holds 88,525 unexercised options in the Company. As of
today, Endre Kjærland holds 1,508 shares in the Company.
The capital increase is expected to be registered within 7 days, and following the issuance of the new shares, the issued share capital of BerGenBio ASA will be
NOK 6,107,659 consisting of 61,076,590 shares, each with a par value of NOK 0.10.
-End-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important
factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or
implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Html version:
- https://publish.ne.cision.com//Release/ViewReleaseHtml/8920B327D17E753BE0C856B0705FC7D6
Redigert 20.01.2021 kl 21:06
Du må logge inn for å svare
Har du ikke sett dette før nå ? Dessuten har CEO 'million lønn' ;)
Redigert 20.01.2021 kl 21:06
Du må logge inn for å svare